Efficacy and safety of Memantine for improvement in cognitive symptoms in depressive patients.

INTERVENTION: Intervention1: Memantine with Escitalopram: Memantine starting fron a dose of 5mg to a maximum dose of 20mg once a day per oral and Escitalopram starting from 5mg to a maximum dose of 20mg once a day per oral given as a single dose or in divided doses adjusted over a period of 2 weeks will be given to MDD patients.These patients will be followed up over a period of 12 weeks. Control Intervention1: Only Escitalopram: Escitalopram starting from 5mg upto a maximum dose of 20mg once a day per oral given as a single dose or in divided doses adjusted over a period of 2 weeks will be given to MDD patients. These patients will be followed up over a period of 12 weeks. CONDITION: Health Condition 1: F329‐ Major depressive disorder, singleepisode, unspecified PRIMARY OUTCOME: Better Improvement in Cognitive domains and MADRS with Memantine as an adjunct. ; ; ; ; Timepoint: Baseline, 6 weeks and 12 weeks SECONDARY OUTCOME: NILTimepoint: NIL INCLUSION CRITERIA: 1.Patients giving written informed consent. 2.Age group of 18‐65 years. 3.Patients with primary education (up to 5th standard or higher ) 4.Patients diagnosed as having major depressive disorder according to DSM‐5‐TR